A phase I study of THX-ULD01 for the treatment of mild cognitive impairment
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs THX-ULD01 (Primary)
- Indications Brain injuries; Cognition disorders
- Focus Adverse reactions; Proof of concept
- Sponsors Therapix Biosciences
- 09 Nov 2017 According to a Therapix Biosciences media release, Institutional Review Board approval has been recieved.
- 09 Nov 2017 Status changed from planning to not yet recruiting, according to a Therapix Biosciences media release.
- 10 Aug 2017 According to a Therapix Biosciences media release, this study will be initiated in the fourth quarter of 2017.